Behçet's syndrome: A critical digest of the 2013-2014 literature

Clinical and Experimental Rheumatology

Volumn 32, Issue , 2014, Pages S112-S122

  Hatemi, Gulen ^a   Seyahi, Emire ^a   Fresko, Izzet ^a   Talarico, Rosaria ^b   Hamuryudan, Vedat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Beh et's syndrome; Clinical manifestations; Epidemiology; Genetics; Management; Pathogenesis; Treatment

Indexed keywords

COLCHICINE; FLUOCINOLONE; HLA ANTIGEN; HLA B ANTIGEN; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR;

AORTA ANEURYSM; ATOPY; BEHCET DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOVASCULAR SURGERY; ETHNIC DIFFERENCE; EYE DISEASE; FEVER; GASTROINTESTINAL DISEASE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; NEUROLOGIC DISEASE; NONHUMAN; OUTCOMES RESEARCH; PERSONALITY DISORDER; PREGNANCY; PREVALENCE; PROGNOSIS; REVIEW; UVEITIS; VASCULAR DISEASE; BEHCET SYNDROME; MORTALITY; RECURRENT DISEASE; TREATMENT OUTCOME;

BEHCET SYNDROME; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROGNOSIS; RECURRENCE; TREATMENT OUTCOME;

EID: 84907533606     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. SAVEY L, RESCHE-RIGON M, WECHSLER B et al.: Ethnicity and association with disease manifestations and mortality in Behçet's disease. Orphanet J Rare Dis 2014; 9: 42.
2. SIBLEY C, YAZICI Y, TASCILAR K et al.: Behçet syndrome manifestations and activity in the United States versus Turkey-A cross-sectional cohort comparison. J Rheumatol 2014 Jun 15.
3. DIRESKENELI H, MUMCU G: A possible decline in the incidence and severity of Behçet's disease: implications for an infectious etiology and oral health. Clin Exp Rheumatol 2010; 28 (Suppl. 60): S86-90.
4. KIM DY, CHOI MJ, CHO S, KIM DW, BANG D: Changing clinical expression of Behçet disease in Korea during three decades (1983-2012): chronological analysis of 3674 hospital-based patients. Br J Dermatol 2014; 170: 458-61.
5. RODRÍGUEZ-CARBALLEIRA M, ALBA MA, SOLANS-LAQUÉ R et al.: Registry of the Spanish network of Behçet's disease: a descriptive analysis of 496 patients. Clin Exp Rheumatol 2014; 32 (Suppl. 84): S33-39.
6. LENNIKOV A, ALEKBEROVA Z, GOLOEVA R et al.: Single center study on ethnic and clinical features of Behçet's disease in Moscow, Russia. Clin Rheumatol 2013.
7. HATEMI G, MERKEL PA, HAMURYUDAN V et al.: Outcome measures used in clinical trials for Behçet syndrome: a systematic review. J Rheumatol 2014; 41: 599-612.
8. KABURAKI T, NAMBA K, SONODA KH et al.; OCULAR BEHÇET DISEASE RESEARCH GROUP OF JAPAN: Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol 2014; 58: 120-30.
9. YILMAZ S, SIMSEK I, CINAR M et al.: Patient-driven assessment of disease activity in Behçet's syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet's Syndrome Activity Score. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 77-83.
10. HATEMI G, YAZICI Y, YAZICI H: Behçet's syndrome. Rheum Dis Clin North Am 2013; 39: 245-61.
11. HATEMI G, SEYAHI E, FRESKO I, HAMURYUDAN V: Behçet's syndrome: a critical digest of the 2012-1213 literature. Clin Exp Rheumatol 2013; 31 (Suppl. 77): S108-S117.
12. HATEMI G, SEYAHI E, FRESKO I, HAMURYUDAN V: Behçet's syndrome: a critical digest of the recent literature. Clin Exp Rheumatol 2012; 30 (Suppl. 72): S80-9.
13. DIRESKENELI H: Innate and adaptive responses to heat shock proteins in Behçet's disease. Genet Res Int 2013; 2013: 249157.
14. AVCI O, ELLIDOKUZ E, SIMSEK I, BUYUKGEBIZ B, GUNES AT: Helicobacter pylori and Behçet's disease. Dermatology 1999; 14: 140-3.
15. CAKMAK SK, CAKMAK A, GUL U, SULAI-MANOV M, BINGOL P, HAZINEDAROGLU MS: Upper gastrointestinal abnormalities and Helicobacter pylori in Behçet's disease. Int J Dermatol 2009; 14: 1174-6.
16. ERSOY O, ERSOY R, YAYAR O, DEMIRCI H, TATLICAN S: H pylori infection in patients with Behçet's disease. World J Gastroenterol 2007; 14: 2983-5.
17. SENTURK O, OZGUR O, HULAGU OS, CANTURK NZ, CELEBI A, KARAKAYA AT: Effect of Helicobacter pylori infection on deep vein thrombosis seen in patients with Behçet's disease. East Afr Med J 2006; 14: 49-51.
18. LANKARANI KB, RAVANBOD MR, AFLAKI E, NAZARINIA MA, RAJAEE A: High prevalence of Helicobacter pylori infection in Behçet's disease. BMC Gastroenterol 2014; 14: 58.
19. CICEK D, DAĞLI AF, AYDIN S et al.: Does hepcidin play a role in the pathogenesis of aphthae in Behçet's disease and recurrent aphthous stomatitis? J Eur Acad Dermatol Venereol 2013 Dec 17.
20. REMMERS EF, COSAN F, KIRINO Y et al.: Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet 2010; 42: 698.
21. MIZUKI N, MEGURO A, OTA M et al.: Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet 2010; 42: 703
22. WU Z, ZHENG W, XU J et al.: IL10 polymorphisms associated with Behçet's disease in Chinese Han. Hum Immunol 2014; 75: 271-6.
23. KURANOV AB, KÖTTER I, HENES JC et al.: Behçet's disease in HLA-B*51 negative Germans and Turks shows association with HLA-Bw4-80I. Arthritis Res Ther 2014; 16: R116
24. OMBRELLO MJ, KIRINO Y, De BAKKER PI et al.: Behçet disease-associated MHC class I residues implicate antigen binding and regulation of cell-mediated cytotoxicity. Proc Natl Acad Sci USA 2014; 111: 8867-72.
25. HUGHES T, COIT P, ADLER A et al.: Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. Nat Genet 2013; 45: 319-24.
26. LEE YJ, HORIE Y, WALLACE GR et al.: Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behçet's disease. Ann Rheum Dis 2013; 72: 1510-6.
27. ORTIZ-FERNÁNDEZ L, CONDE-JALDÓN M, GARCÍA-LOZANO JR et al.: GIMAP and Behçet disease: no association in the European population. Ann Rheum Dis 2014; 73: 1433-4.
28. HOU S, QI J, LIAO D et al.: Copy number variations of complement component C4 are associated with Behçet's disease but not with ankylosing spondylitis associated with acute anterior uveitis. Arthritis Rheum 2013; 65: 2963-70.
29. QI J, HOU S, ZHANG Q et al.: A functional variant of pre-miRNA-196a2 confers risk for Behçet's disease but not for Vogt-Koyanagi-Harada syndrome or AAU in ankylosing spondylitis. Hum Genet 2013; 132: 1395-404.
30. ZHOU Q, HOU S, LIANG L et al.: MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behçet's disease and Vogt-Koyanagi-Harada syndrome. Ann Rheum Dis 2014; 73: 170-6.
31. KANG EH, PARK JW, PARK C et al.: Genetic and non-genetic factors affecting the visual outcome of ocular Behçet's disease. Hum Immunol. 2013;74:1363-7.
32. KIM SJ, LEE S, PARK C, SEO JS, KIM JI, YU HG: Targeted resequencing of candidate genes reveals novel variants associated with severe Behçet's uveitis. Exp Mol Med 2013; 45: e49.
33. CHAMORRO AJ, MARCOS M, HERNÁNDEZ-GARCÍA I et al.: Association of allelic variants of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase with thrombosis or ocular involvement in Behçet's disease: a systematic review and meta-analysis. Autoimmun Rev 2013; 12: 607-16.
34. TURUNC G, COSKUN D, ALIBAZ-ONER F et al.: TIR-domain-containing adaptor protein gene TIRAP S180L polymorphism is not increased in Behçet's disease patients in two ethnic cohorts. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 54-6.
35. FANG J, HU R, HOU S et al.: Association of TLR2 gene polymorphisms with ocular Behçet's disease in a Chinese Han population. Invest Ophthalmol Vis Sci 2013; 54: 8384-92.
36. DURSUN A, CICEK S, KENI FM, KARAKAS-CELIK S, SEZER T, ALTINYAZAR CH: The relation of PON1-L55M gene polymorphism and clinical manifestation of Behçet's disease. Acta Biochim Pol 2014; 61: 271-4.
37. TIZAOUI K, KAABACHI W, OULED SALAH M, BEN AMOR A, HAMZAOUI A, HAMZAOUI K: Vitamin D receptor TaqI and ApaI polymorphisms: A comparative study in patients with Behçet's disease and Rheumatoid arthritis in Tunisian population. Cell Immunol 2014; 290: 66-71.
38. FANG J, HOU S, XIANG Q et al.: Polymorphisms in genetics of vitamin D metabolism confer susceptibility to ocular Behçet disease in a Chinese Han population. Am J Ophthalmol 2014; 157: 488-94.
39. XAVIER JM, KRUG T, DAVATCHI F et al.: Gene expression profiling and association studies implicate the neuregulin signaling pathway in Behçet's disease susceptibility. J Mol Med 2013; 91: 1013-23.
40. HOU S, QI J, ZHANG Q et al.: Genetic variants in the JAK1 gene confer higher risk of Behçet's disease with ocular involvement in Han Chinese. Hum Genet 2013; 132: 1049-58.
41. + T cells from patients with Behçet's disease. Arthritis Rheumatol 2014; 66: 1648-58.
42. ALP R, GUNEY AU, TURSEN U, KAYA T, TURSEN B, ERDAL ME: Microchimerism in Behçet's disease. Int J Dermatol 2014; 53: 832-7.
43. ZHANG M, XU WD, WEN PF et al.: Poly-morphisms in the tumor necrosis factor gene and susceptibility to Behçet's disease: an updated meta-analysis. Mol Vis 2013; 19: 1913-24.
44. WANG C, TIAN Y, YE Z, KIJLSTRA A, ZHOU Y, YANG P: Decreased interleukin-27 expression is associated with active uveitis in Behçet's disease. Arthritis Res Ther 2014; 16: R117.
45. YE Z, WANG C, KIJLSTRA A, ZHOU X, YANG P: A possible role for interleukin 37 in the pathogenesis of Behçet's disease. Curr Mol Med. 2014; 14: 535-42.
46. HAMZAOUI K, KAABACHI W, FAZAA B, ZAKRAOUI L, MILI-BOUSSEN I, HAJ-SASSI F: Serum IL-33 levels and skin mRNA in Behçet's disease. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 6-14.
47. HAMZAOUI K, BORHANI-HAGHIGHI A, KAABACHI W, HAMZAOUI A: Increased interleukin 33 in patients with neuro-Behçet's disease: correlation with MCP-1 and IP-10 chemokines. Cell Mol Immunol 2014 Jun 9.
48. NA SY, PARK MJ, PARK S, LEE ES: Up-regulation of Th17 and related cytokines in Behçet's disease corresponding to disease activity. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 32-40.
49. YOSHIOKA T, KUROKAWA MS, SATO T et al.: Protein profiles of peripheral blood mononuclear cells as a candidate biomarker for Behçet's disease. Clin Exp Rheumatol 2014; 32 (Suppl. 84): S9-19.
50. OZYAZGAN S, UZUN H, ONAL B, TUZCU A, UGURLU S, ANDICAN G: Lectin-like oxidised LDL receptor-1 as a marker of endothelial dysfunction in Behçet's disease. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 71-6.
51. EMMI G, SILVESTRI E, CAMELI AM et al.: Anakinra for resistant Behçet uveitis: why not? Clin Exp Rheumatol 2013; 31 (Suppl. 77): 152-3.
52. TUGAL-TUTKUN I, ONAL S, OZYAZGAN Y, SOYLU M, AKMAN M: Validity and Agreement of Uveitis Experts in Interpretation of Ocular Photographs for Diagnosis of Behçet Uveitis. Ocul Immunol Inflamm 2013 Dec 11.
53. YOSHIDA A, KAWASHIMA H, MOTOYAMA Y et al.: Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 2004; 111: 810-5.
54. CINGU AK, ONAL S, URGANCIOGLU M, TUGAL-TUTKUN I: Comparison of presenting features and three-year disease course in Turkish patients with Behçet uveitis who presented in the early 1990s and the early 2000s. Ocul Immunol Inflamm 2012; 20: 423-8.
55. CHUNG YR, LEE ES, KIM MH, LEW HM, SONG JH: Changes in Ocular Manifestations of Behçet Disease in Korean Patients over Time: A Single-center Experience in the 1990s and 2000s. Ocul Immunol Inflamm 2014; 27: 1-5.
56. KANG HM, LEE SC: Long-term progression of retinal vasculitis in Behçet patients using a fluorescein angiography scoring system. Graefes Arch Clin Exp Ophthalmol 2014; 252: 1001-8.
57. TASCILAR K, MELIKOGLU M, UGURLU S, SUT N, CAGLAR E, YAZICI H: Vascular involvement in Behçet's syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014 Jun 6.
58. SEYAHI E, MELIKOGLU M, AKMAN C et al.: Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore). 2012; 91: 35-48.
59. ZHANG X, DAI H, MA Z, YANG Y, LIU Y: Pulmonary involvement in patients with Behçet's disease: report of 15 cases. Clin Respir J 2014 Apr 24.
60. AOYAGI R, SAKAI T, KONO Y, IGUCHI Y, TSUNEOKA H: A case of Behçet's disease with development of MS-like lesions in the CNS and spinal cord. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 154.
61. NEVES FS, FERREIRA RM, PEREIRA IA, ZIMMERMANN AF, LIN K: Neuro-Behçet's disease, its mimickers and anti-TNF therapy: a case-based review. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 133-40.
62. NOEL N, BERNARD R, WECHSLER B et al.: Long-Term Outcome of Neuro-Behçet's Disease. Arthritis Rheum 2014 Jan 8.
63. SIVA A, KANTARCI OH, SAIP S et al.: Behçet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 2001; 248: 95-103.
64. AKMAN-DEMIR G, SERDAROGLU P, TASCI B, AND THE NEURO-BEHçET STUDY GROUP: Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. Brain 1999; 122: 2171-82.
65. HOUMAN MH, BELLAKHAL S, BEN SALEM T et al.: Characteristics of neurological manifestations of Behçet's disease: a retrospective monocentric study in Tunisia. Clin Neurol Neurosurg 2013; 115: 2015-8.
66. KIKUCHI H, TAKAYAMA M, HIROHATA S: Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Behçet's disease. J Neurol Sci 2014; 337: 80-5.
67. UYGUNOĞLU U, BENBIR G, SAIP S, KAYNAK H, SIVA A: A polysomnographic and clinical study of sleep disorders in patients with Behçet and neuro-Behçet syndrome. Eur Neurol 2014; 71: 115-9.
68. TAŞOLAR S, DOĞAN M, TAŞOLAR H et al.: Evaluation of vertebral artery involvement by Doppler sonography in patients with Behçet disease. J Ultrasound Med 2014; 33: 811-6.
69. YIM SM, KIM DH, LEE HJ et al.: Mucosal healing predicts the long-term prognosis of intestinal Behçet's disease. Dig Dis Sci 2014 May 18.
70. JUNG YS, CHEON JH, PARK SJ, HONG SP, KIM TI, KIM WH: Long-term clinical outcomes of Crohn's disease and intestinal Behçet's disease. Inflamm Bowel Dis 2013; 19: 99-105.
71. HUNG CH, LEE JH, CHEN ST et al.: Young children with Behçet disease have more intestinal involvement. J Pediatr Gastroenterol Nutr 2013; 57: 225-9.
72. HISAMATSU T, UENO F, MATSUMOTO T et al.: The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet's disease: indication of anti-TNF-α monoclonal antibodies. J Gastroenterol 2014; 49: 156-62.
73. HATEMI G, SILMAN A, BANG D et al.: EULAR Expert Committee. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 1656-62.
74. SEYAHI E, KARAASLAN H, UGURLU S, YAZICI H: Fever in Behçet's syndrome. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 64-7.
75. NOEL N, WECHSLER B, NIZARD J et al.: Behçet's disease and pregnancy. Arthritis Rheum 2013; 65: 2450-6
76. ISKENDER C, YASAR O, KAYMAK O, YAMAN ST, UYGUR D, DANISMAN N: Behçet's disease and pregnancy: A retrospective analysis of course of disease and pregnancy outcome. J Obstet Gynaecol Res 2014; 40: 1598-602.
77. LIN Y, LI G, ZHENG W, TIAN X, ZHANG F: Behçet's disease associated with malignancy: a report of 41 Chinese cases. Int J Rheum Dis 2014; 17: 459-65.
78. YETKIN DO, CELIK O, HATEMI G, KADIOGLU P: Sexual dysfunction and depression in premenopausal women with mucocutaneous Behçet's disease. Int J Rheum Dis 2013; 16: 463-8.
79. ATAY IM, ERTURAN I, DEMIRDAS A, YAMAN GB, YüREKLI VA: The impact of personality on quality of life and disease activity in patients with Behçet's disease: a pilot study. Compr Psychiatry 2014; 55: 511-7.
80. YAZICI A, ORGE GONULLU E, KARDES B, CEFLE A: The prevalence of atopy in patients with familial Mediterranean fever and Behçet's disease. Clin Exp Rheumatol 2013; 31 (Suppl. 77): 68-70.
81. SAIP S, AKMAN-DEMIR G, SIVA A: Neuro-Behçet syndrome. Handb Clin Neurol 2014; 121: 1703-23.
82. MAT C, YURDAKUL S, SEVIM A, ÖZYAZGAN Y, TüZüN Y: Behçet's syndrome: facts and controversies. Clin Dermatol 2013; 31: 352-61.
83. WALLACE GR: HLA-B*51 the primary risk in Behçet disease. Proc Natl Acad Sci USA 2014 May 29.
84. KALRA S, SILMAN A, AKMAN-DEMIR G et al.: Diagnosis and management of Neuro-Behçet's disease: international consensus recommendations. J Neurol 2013 Dec 24.
85. HAMURYUDAN V, HATEMI G, TASCILAR K et al.: Colchicine in Behçet syndrome: A long-term survey of patients enrolled in a controlled trial. J Rheumatol 2014; 41: 735-8.
86. LEE JH, CHEON JH, JEON SW et al.: Efficacy of infliximab in intestinal Behçet's disease: A Korean multicenter retrospective study. Inflamm Bowel Dis 2013; 19: 1833-8.
87. KINOSHITA H, KUNISAKI R, YAMAMATO H et al.: Efficacy of infliximab in patients with intestinal Behçet's disease refractory to conventional medication. Intern Med 2013; 52: 1855-62.
88. Al-RASHIDI S, Al FAWAZ A, KANGAVE D, ABU El-ASRAR A: Long-term clinical outcomes in patients with refractory uveitis associated with Behçet disease treated with infliximab. Ocul Immunol Inflamm 2013; 21: 468-74.
89. KAWAGUCHI T, KAWAZOE Y, KAMOI K et al.: Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy. Jpn J Ophthalmol 2014; 58: 75-80.
90. KIM SW, LEE DO Y, KIM MD et al.: Outcomes of endovascular treatment for aortic pseudoaneurysm in Behçet's disease. J Vasc Surg. 2014; 59: 608-14.
91. OH EK, LEE EK, YU HG: Long-term results of fluocinolone intravitreal implant in Behçet intractable uveitis. Can J Ophthalmol 2014; 49: 273-8.
92. PARK UC, PARK JH, YU HG: Long-term outcome of intravitreal triamcinolone acetonide injection for the treatment of uveitis attacks in Behçet disease. Ocular Immunol Inflamm 2014; 22: 27-33.